## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.4% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($243.22)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. movimientos de acciones de Labcorp Holdings (NYSE:LH)**
- Source: Simply Wall Street | 20260101T120819 | Somewhat-Bullish | Relevance: 100%
- Labcorp Holdings (NYSE:LH) shareholders have seen a 7.1% CAGR over the last five years, with the stock up 16% in that period, although this is below the market return of 76%. The company's earnings per share (EPS) grew at 3.5% annually over five years, closely tracking the 3% share price gain. When considering total shareholder return (TSR), which includes dividends, Labcorp Holdings shows a 41% return over five years, significantly better than the share price return alone.

**2. Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: BioSpace | 20251231T051010 | Somewhat-Bullish | Relevance: 100%
- Labcorp (NYSE: LH) announced its participation in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, at 4:30 p.m. PT. A live audio webcast will be available on the company's Investor Relations website. Labcorp is a global leader in laboratory services, providing diagnostics and drug development capabilities to clients in approximately 100 countries.

**3. Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: Barchart.com | 20251231T070837 | Neutral | Relevance: 100%
- Labcorp (NYSE: LH) announced it will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, at 4:30 p.m. PT. A live audio webcast will be available on the Company's Investor Relations website. Labcorp is a global leader in laboratory services, supporting medical decisions and drug development.

**4. Allspring Global Investments Holdings LLC Lowers Stake in Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251231T084821 | Somewhat-Bullish | Relevance: 96%
- Allspring Global Investments Holdings LLC reduced its stake in Labcorp Holdings Inc. by 0.2% in the third quarter, while still holding a significant position. Insiders, including Director Richelle P. Parham and CEO Adam H. Schechter, also sold shares, decreasing insider ownership to about 0.84%. Labcorp exceeded Q3 EPS estimates, saw an 8.6% increase in revenue, and set strong FY2025 guidance, with analysts maintaining a "Moderate Buy" rating and a consensus target price of nearly $299.

**5. NeoGenomics appoints diagnostics veteran Jack Kenny to board By Investing.com**
- Source: Investing.com Nigeria | 20251231T060927 | Neutral | Relevance: 57%
- NeoGenomics, Inc. has appointed John P. "Jack" Kenny, a diagnostics industry veteran with over 30 years of experience, to its Board of Directors. Kenny's appointment fills the vacancy left by Dr. Alison Hannah and is expected to support the company's growth in next-generation cancer testing. This news follows strong third-quarter earnings for 2025 and a favorable patent dispute ruling for NeoGenomics.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.9B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 14.4 |
| Current P/E | 15.4 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.2% to -1.4% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.4pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Underperforming sector by 3.1pp, stock-specific weakness. Below SMA200 (0.97x), long-term trend not supportive. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.43% (CS: 23) | Neutral |
| RSI_14 | 38.1 | Neutral |
| MACD Histogram | -0.35 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.975x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $251.66
- **Stop Loss:** $243.22 (3.4% risk)
- **Target:** $260.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $42,782.20
- **Portfolio %:** 42.78%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*